March 05, 2015 7:29 PM ET


Company Overview of Zalicus Inc.

Company Overview

As of July 15, 2014, Zalicus Inc. was acquired by EPIRUS Biopharmaceuticals, Inc., in a reverse merger transaction. Zalicus Inc., a biopharmaceutical company, discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company has collaboration agreements with Mallinckrodt Inc.; Fovea Pharmaceuticals SA; Institutes of BioMedical Research, Inc.; Amgen I...

245 First Street

Third Floor

Cambridge, MA 02142

United States

Founded in 2000

21 Employees





Key Executives for Zalicus Inc.

Zalicus Inc. does not have any Key Executives recorded.

Zalicus Inc. Key Developments

Zalicus Inc. Reports Unaudited Earnings Results for the Quarter Ended March 31, 2014

Zalicus Inc. reported consolidated unaudited earnings results for the quarter ended March 31, 2014. For the quarter, the company reported total revenue of $1,603,000 compared with $14,731,000 for the same period last year. Loss from operations was $3,488,000 compared with $37,210,000 for the same period last year. Loss before income taxes was $3,790,000. Net loss was $3,790,000 or $0.15 basic and diluted per share compared with $38,617,000 or $1.68 basic and diluted per share for the same period last year. Adjusted loss from operations was $4,279,000 compared with $41,311,000 for the same period last year. Adjusted loss before income taxes before income taxes was $4,305,000. Adjusted net loss was $4,305,000 or $0.16 basic and diluted per share compared with $41,612,000 or $1.81 basic and diluted per share for the same period last year.

Zalicus Inc.(NasdaqCM:ZLCS) dropped from NASDAQ Composite Index

Zalicus Inc. will be removed from the NASDAQ Composite Index.

Fovea Pharmaceuticals Enters into Agreement to Terminate Second Amended and Restated License Agreement

Zalicus Inc. and Fovea Pharmaceuticals on June 30, 2014, entered into an agreement pursuant to which the parties mutually agreed to terminate that second amended and restated license agreement, dated July 22, 2009, between the parties. Following this termination, Zalicus assigned certain of its patents which had previously been licensed under the 2009 Agreement to a third party controlled by certain former owners of Fovea. This third party may exploit these patent rights independently or in conjunction with another third party.

Similar Private Companies By Industry

Company Name Region
Molecular Imaging Products Company United States
International Oilseed Distributors, Inc. United States
AxCell Biosciences Corporation United States
Irvine Scientific Sales Company, Inc. United States
Xylos Corporation United States

Recent Private Companies Transactions

May 15, 2014
Zalicus Inc., CombinatoRx Service Business and Assets
April 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zalicus Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at